Braskem S.A. (BAK) Stock Analysis

Company Overview

Braskem S.A. operates as a manufacturer, seller, importer, and exporter of chemicals, petrochemicals, and fuels within the Brazilian market. The company functions within the Basic Materials sector, specifically in the Chemicals industry, where it focuses on the production and distribution of essential feedstocks and finished polymers. Its scale is reflected in a market capitalization of $1.67B and a trailing twelve-month revenue of $73.77B, while the specific employee count is not publicly disclosed in the available data. These valuation and revenue figures indicate that the company maintains a significant operational footprint, generating substantial top-line sales despite facing financial challenges that have impacted its equity value. The disparity between the high revenue volume and the modest market cap suggests that current market pricing heavily discounts the firm's earnings potential or asset base due to recent performance metrics.

Financial Health

The company reported a revenue of $73.77B for the trailing twelve months, yet it recorded a net income of $-5,241,999,872 and an EBITDA of $-355,000,000. The substantial gap between the $73.77B in revenue and the negative net income reveals a highly leveraged cost structure where operating expenses and interest costs significantly erode profitability. Free cash flow stands at $-7,746,124,800, indicating that the company is currently consuming cash rather than generating it, which constrains financial flexibility and limits the ability to fund operations without external financing. Margins reflect this distress, with a gross margin of 4.4%, an operating margin of -9.7%, and a profit margin of -7.1%, all signaling inefficiencies or high input costs relative to sales. On the balance sheet, total cash of $7.41B is held against total debt of $63.24B, creating a highly leveraged position where liabilities vastly exceed liquid assets. Although the debt-to-equity ratio is not listed, the negative price-to-book of -4.96 and negative forward P/E of -2.23 suggest the market prices the firm as having liabilities that exceed its tangible equity. Liquidity is tight but manageable with a current ratio of 1.18, which indicates the company holds sufficient current assets to cover short-term obligations, though the margin is narrow. Return on Equity is not available, while Return on Assets is -2.8%, revealing that the company's assets are currently generating negative returns on the capital invested by shareholders.

Valuation Assessment

Valuation metrics present a complex picture, with a trailing P/E ratio listed as N/A and a forward P/E of -2.23, implying that future earnings are not expected to be sufficient to justify the current share price. The price-to-book ratio is -4.96, which indicates that the market values the company at less than its book value, a situation often associated with significant debt or operational losses. Alternative valuation metrics such as the price-to-sales ratio of 0.02 and an EV/EBITDA of -167.71 further suggest that traditional earnings-based models are not applicable due to the lack of profitability. The stock has traded between a 52-week high of $5.29 and a 52-week low of $2.32, placing the current valuation well below the recent peak and reflecting a depressed market sentiment. With a beta of 0.85, the stock exhibits lower volatility than the broader market, suggesting that its price movements are less sensitive to general market fluctuations compared to high-beta equities. These metrics collectively indicate a firm that is currently priced for survival rather than growth, with valuation multiples that do not reflect typical industry norms for profitable chemical manufacturers.

Growth & Income

Revenue growth for the year-over-year period stands at -18.6%, while earnings growth is N/A, indicating a contraction in top-line sales that has directly impacted profitability. The decline in revenue implies that the company is facing headwinds in demand or pricing power that are not being offset by volume increases. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company retains all earnings rather than distributing them to shareholders, likely due to the need to service its substantial debt obligations. The overall growth and income profile is characterized by significant revenue contraction and a complete absence of dividend income, reflecting a capital allocation strategy focused on liquidity preservation rather than shareholder returns.